Karakterisasi dan Formulasi Uji Sitotoksik Nanopartikel PLGA-pcDNA 3.1-SB3-HBcAg dari Gel Retardation Assay sebagai Delivery Agent Kandidat Vaksin DNA Hepatitis B
Characterization and Cytotoxic Test Formulation of PLGA-pcDNA 3.1-SB3-HBcAg Nanoparticles from Gel Retardation Assay as Delivery Agent for Hepatitis B DNA Vaccine Candidate
Indonesia is one of the countries that has the highest prevalence of HBsAg (hepatitis B disease), ranging from 2.5% to 10%, with the highest levels reported in North Sulawesi with 33.0%, Papua with 12.8%, and Pontianak with 9.1%. Strategies to overcome these obstacles include using formulations such as nanoparticles, which are formed by coacervation between polymers and DNA. This study showed that the results of the physicochemical characterization of PLGA-pcDNA 3.1-SB3-HBcAg showed a polydispersity index value of 0.246, a particle size of 925 nm, and a zeta potential value of 2.31 mV. PLGA managed to protect PLGA-pcDNA 3.1-SB3-HBcAg from enzymatic degradation, and the viability percentage of the PLGA-pcDNA 3.1-SB3-HBcAg cytotoxicity test was 98.03%, so that PLGA has good potential as a delivery system for PLGA -pcDNA 3.1-SB3- HBcAg.
Akbar, S, M, F., Al-Mahtab, M., Uddin, M, H., & Khan, S, I. (2013). HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int, 12(4), 363–369.
Avadi, M, R., Sadeghi, A, M, M., Mohammad pour, N., Abedin, S., Atyabi, F., Dinarvand, R., & Rafiee-Tehrani, M. (2010). Preparation and Characterization of Insulin Nanoparticles Using Chitosan and Arabic Gum with Ionic Gelation Method. Nanomedicine: Nanotechnology, Biology and Medicine, 6(1), 58–63.
Danhier, F., Ansorena, E., Silva, J, M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522. Retrieved from https://doi.org/https://doi.org/10.1016/j.jconrel.2012.01.043
Fröhlich, E. (2012). The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. International Journal of Nanomedicine, 7, 5577–5591. Retrieved from https://doi.org/10.2147/IJN.S36111
Gao, L., Zhang, D., & Chen, M. (2008). Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and Its Application as a Potential Drug Delivery System. J. Nanopart, 10, 845–862.
Huang, T., Song, X., Jing, J., Zhao, K., Shen, Y., Zhang, X., & Yue, B. (2018). Chitosan ‑ DNA Nanoparticles Enhanced The Immunogenicity of Multivalent DNA Vaccination on Mice agaInst Trueperella pyogenes Infection. Journal of Nanobiotechnology, 16(8), 1–15.
Ishak, J., Unsunnidhal, L., Martien, R., & Kusumawati, A. (2019). In vitro evaluation of chitosan-DNA plasmid complex encoding Jembrana disease virus Env-TM protein as a vaccine candidate. Journal of Veterinary Research, 63(1), 7–16. Retrieved from https://doi.org/https://doi.org/10.2478/jvetres-2019-0018
Kalvanagh, P, A., Ebtekar, M., Kokhaei, P., & Soleimanjahi, H. (2019). Preparation and Characterization of PLGA Nanoparticles Containing Plasmid DNA Encoding Human IFN-Lambda-1/IL-29. Iranian Journal of Pharmaceutical Research, 18(1), 156–167.
Lokhande. (2011). HBV and HCV immunophatogenesis, in mukolov SL,Viral hepatitis, selected issues of phatogenesis and diagnostics intech open. Croatia.
Lúcio, M., Carvalho, A., Lopes, I., Gonçalves, O., Bárbara, E., & Oliveira, M. (2015). Polymeric Versus Lipid Nanoparticles: Comparative Study of Nanoparticulate Systems as Indomethacin Carriers. Journal of Applied Solution Chemistry and Modeling, 4(2), 95–109.
Mohanraj, V, J., & Chen, Y. (2006). Nanoparticles-A Review. Tropical Journal of Pharmaceutical Research, 5(1), 561–573.
Mura, S., Hillaireau, H., Nicolas, J., Le Droumaguet, B., Gueutin, C., Zanna, S., … Fattal, E. (2011). Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. International Journal of Nanomedicine, 6, 2591–2605. Retrieved from https://doi.org/10.2147/ijn.s24552
Palocci, C., Valletta, A., Chronopoulou, L., Donati, L., Bramosanti, M., Brasili, E., … Pasqua, G. (2017). Endocytic pathways involved in PLGA nanoparticle uptake by grapevine cells and role of cell wall and membrane in size selection. Plant Cell Reports, 36(12), 1917–1928. Retrieved from https://doi.org/10.1007/s00299-017-2206-0
Qingguo, X., Alison, C., & Jan, C. (2009). Preparation and Characterization of Negatively Charged Poly(Lactic-co-Glycolic Acid) Microspheres. Journal of Pharmaceutical Sciences, 98(7), 2377–2389.
Ravi Kumar, M, N, V., Bakowsky, U., & Lehr, C, M. (2004). Preparation and Characterization of Cationic PLGA Nanospheres as DNA Carriers. Biomaterials, 25(10), 1771–1777.
Unsunnidhal, L, Ishak, J., & Kusumawati, A. (2019). Expression of gag-CA Gene of Jembrana Disease Virus with Cationic Liposomes and Chitosan Nanoparticle Delivery Systems as DNA Vaccine Candidates. Tropical Life Sciences Research, 30(3), 15–36. Retrieved from https://doi.org/https://doi.org/10.21315/tlsr2019.30.3.2
Unsunnidhal, Lalu, Jannah, R., Haris, A., Supinganto, A., & Kusumawati, A. (2021). Potential of Nanoparticles Chitosan for Delivery pcDNA3.1-SB3- HBcAg. BIO Web of Conferences, 41(07003), 1–6.
Unsunnidhal, Lalu, Wasito, R., Setyawan, E. M. N., & Kusumawati, A. (2021). Potential of Nanoparticles Chitosan for Delivery pcDNA3.1-tat. BIO Web of Conferences, 41(07004), 1–6.
World Health Organization. (2020). Global Tuberculosis Report 2020. Retrieved from Geneva, Switzerland:
Zhao, K., Li, G. X., Jin, Y. Y., Wei, H. X., Sun, Q. S., Huang, T. T., & Tong, G. Z. (2010). Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres. Journal of Microencapsulation, 27(2), 178–186. Retrieved from https://doi.org/https://doi.org/10.3109/02652040903059239
Zhao, K., Zhang, Y., Zhang, X., Shi, C., Wang, X., Wang, X., & Cui, S. (2014). Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine. Chitosan-Coated Poly(Lactic-Co-Glycolic) Acid Nanoparticles as an Efficient Delivery System for Newcastle Disease Virus DNA Vaccineq, 9(1), 4609–4619. Retrieved from https://doi.org/10.2147/IJN.S70633
Copyright (c) 2023 Lalu Unsunnidhal, Raudatul Jannah, Fihiruddin, Nurul Inayati, Agus Supinganto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY), that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).